Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyMedical Mutual - Ohio Egrifta Prior Auth Policy | …
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Recommended Authorization Criteria — Egrifta (tesamorelin)

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Recommended prior authorization criteria for coverage of Egrifta (tesamorelin) for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; applies to pharmacy benefit coverage determinations by Medical Mutual - Ohio.

    Policy Summary
    Payermedical mutual - ohio
    PolicyRecommended Authorization Criteria — Egrifta (tesamorelin)
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain prior authorization and ensure prescription is by or in consultation with an endocrinologist or HIV specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum patient age for coverage
    6 moinitial approval duration
    6 moextended approval duration
    ≥8 wksantiretroviral stability required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    waist criteria
    anthropometric thresholds

    Coverage Criteria

    Initial therapy criteria

    Covered when ALL of the following are met:

    ALL of the following

    • ALL of the following

      • Patient is at least 18 years of age (>= 18).
    • ALL of the following

      • No disruption of the hypothalamic-pituitary axis (e.g., hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma).
      • No active malignancy.
      • Patient is not pregnant.
    • ALL of the following

      • Prescribed by or in consultation with an endocrinologist or HIV specialist.
      • Indication: prescribed for reduction of excess abdominal (visceral) fat in HIV-associated lipodystrophy.
    • ONE of the following anthropometric criteria

      • Male: waist circumference >= 95 cm (37.4 in) AND waist-to-hip ratio >= 0.94.
      • Female: waist circumference >= 94 cm (37 in) AND waist-to-hip ratio >= 0.88.
    • ALL of the following

      • Patient has been stable on an antiretroviral regimen for at least 8 weeks.

    Continuation therapy criteria

    Covered when ALL of the following are met:

    ALL of the following

    • ALL of the following

      • Patient is at least 18 years of age (>= 18).
    • ALL of the following

      • Patient is not pregnant.
    • ALL of the following

      • Prescribed by or in consultation with an endocrinologist or HIV specialist.
    • ALL of the following

    Initial Therapy

    Initial therapy

    Initial authorization is recommended when ALL of the following are satisfied:

    ALL of the following

    • ALL of the following

      • Patient is at least 18 years of age.
    • ALL of the following

      • No disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma).
      • No active malignancy.
      • Patient is not pregnant.

    Continuation Criteria

    Continuation therapy

    Continuation/renewal is recommended when ALL of the following are met:

    ALL of the following

    • ALL of the following

      • Patient is at least 18 years of age.
    • ALL of the following

      • Patient is not pregnant.
    • ALL of the following

      • Prescribed by or in consultation with an endocrinologist or HIV specialist.
    • ALL of the following

    Anthropometric Thresholds & Stability

    inv-03: waist circumference / waist-to-hip ratio
    Male anthropometric thresholdWaist circumference ≥ 95 cm (37.4 in) AND waist-to-hip ratio ≥ 0.94
    Female anthropometric thresholdWaist circumference ≥ 94 cm (37 in) AND waist-to-hip ratio ≥ 0.88
    Measurement contextCriteria apply as part of initial therapy authorization for HIV-associated lipodystrophy
    inv-04: stability on antiretroviral regimen
    Required antiretroviral stabilityStable on an antiretroviral regimen for at least 8 weeks prior to initiation
    ApplicabilityPart of initial therapy criteria for Egrifta in HIV-associated lipodystrophy

    Provider Actions & Administrative Requirements

    Prior Authorization

    Prior authorization and specialist prescriber requirement

    Prior authorization is recommended for pharmacy benefit coverage of Egrifta. Initial approvals must be prescribed by or in consultation with a physician who specializes in the condition being treated (e.g., an endocrinologist or HIV specialist).

    • Initial approvals require specialist prescription or documented consultation.
    • All initial approvals are for the initial approval duration; continuation requires demonstrated response to therapy unless otherwise noted.
    Denial Risk

    Provide documentation on request — denial risk if not supplied or not medically necessary

    The Company may request additional documentation (patient records, test results, provider credentials) to support coverage decisions. Reimbursement may be denied if the drug or services are determined to be not medically necessary, investigational/experimental, outside member benefits, or if billing/practice patterns are inappropriate or excessive.

    Definitions

    inv-08: sex definition for anthropometric thresholds
    Definition of 'men' for thresholdsMen are defined as individuals with the biological traits of a man, regardless of the individual's gender identity or gender expression
    PurposeUsed to interpret sex-specific waist circumference and waist-to-hip ratio criteria for initial authorization
    ScopeDefinition applies where the policy specifies male/female anthropometric thresholds
    Policy Summary
    Payermedical mutual - ohio
    PolicyRecommended Authorization Criteria — Egrifta (tesamorelin)
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateDec 18, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2025
    Key ActionObtain prior authorization and ensure prescription is by or in consultation with an endocrinologist or HIV specialist.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation CriteriaAnthropometric Thresholds & StabilityProvider Actions & Administrative RequirementsDefinitions
    Evidence of improvement based on waist circumference measurement or CT scan.
  1. ALL of the following

    • Prescribed by or in consultation with an endocrinologist or HIV specialist.
  2. ALL of the following

    • Prescribed for reduction of excess abdominal (visceral) fat in HIV-associated lipodystrophy.
  3. Anthropometric threshold (one must apply)

    • Male: waist circumference >= 95 cm (37.4 in) AND waist-to-hip ratio >= 0.94.
    • Female: waist circumference >= 94 cm (37 in) AND waist-to-hip ratio >= 0.88.
  4. ALL of the following

    • Stable on an antiretroviral regimen for at least 8 weeks prior to initiation.
    • Evidence of improvement documented by reduction in waist circumference or by CT scan.
  5. ALL of the following

    • Initial approval: 6 months.
    • Extended approval: 6 months (requires documented response as above).
  6. Minimum age tie-in
    Used together with other initial criteria including patient age ≥ 18 years
    • Provide patient records, relevant test results, and provider credentials upon request.
    • Failure to supply requested documentation or evidence of non‑medical necessity may result in denial of reimbursement.
    Prior Authorization

    Approval durations and requirement for demonstrated response

    Initial authorization is granted for 6 months; extended (reauthorization) approval is also 6 months. Continuation of therapy requires evidence of response to treatment (response to therapy is required for continuation unless otherwise noted).

    • Initial Approval: 6 months.
    • Extended Approval: 6 months.
    • Reauthorization requires documented response to therapy for continuation.